ACADIA Pharmaceuticals Inc. Common Stock (ACAD)
Stock · NASDAQ · Health Care
$19.14as of 10/16/2026
Price chart
Active signals
ACAD Signal Track Record
How signals performed across all stocks →What ACAD's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 33 | -2.2% | 39% | September 18, 2026 |
| Bollinger Band Breakout | 26 | +3.3% | 62% | August 4, 2026 |
| Bollinger Band Breakdown | 19 | -2.1% | 42% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -2.8% | 44% | June 24, 2026 |
| Any 20-session window (baseline) | 0.0% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ACAD
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 796
- Website
- acadia.com/
Fundamentals
- 1-day range
- $18.87$19.76
- Market cap
- $4.87B
- P/E (trailing)
- 8.79
- P/E (forward)
- 20.77
- EPS (trailing)
- $2.21
- Dividend yield
- —
- Beta
- 0.91
- Avg. volume
- 1.86M
How ACADIA Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
19 analyst ratings
ACADIA Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ACADACADIA Pharmaceuticals Inc. Common Stock$19.12▼ 2.99%Market cap $4.87BP/E 8.79$18.39$30.96
- DYNDyne Therapeutics Inc. Common Stock$14.25▼ 6.80%Market cap $4.83BP/E —$13.88$27.31
- INDVIndivior Pharmaceuticals Inc. Common Stock$32.45▼ 3.48%Market cap $4.82BP/E 11.25$23.67$42.81
- EWTXEdgewise Therapeutics Inc. Common Stock$37.19▼ 2.64%Market cap $4.78BP/E —$14.25$48.51
- MANEVeradermics Incorporated Common Stock$108.82▼ 5.43%Market cap $4.54BP/E —$32$136.72
- GRFSGrifols S.A. American Depositary Shares$7.64▲ 1.33%Market cap $5.38BP/E 12.88$8.43$12.15
- PBLSParabilis Medicines Inc. Common Stock$22.75▼ 9.65%Market cap $4.23BP/E —$24.51$42.49
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals Inc. Common Stock | $4.87B | 8.79 | $19.12 | ▼ 2.99% | $18.39$30.96 |
| DYN Dyne Therapeutics Inc. Common Stock | $4.83B | — | $14.25 | ▼ 6.80% | $13.88$27.31 |
| INDV Indivior Pharmaceuticals Inc. Common Stock | $4.82B | 11.25 | $32.45 | ▼ 3.48% | $23.67$42.81 |
| EWTX Edgewise Therapeutics Inc. Common Stock | $4.78B | — | $37.19 | ▼ 2.64% | $14.25$48.51 |
| MANE Veradermics Incorporated Common Stock | $4.54B | — | $108.82 | ▼ 5.43% | $32$136.72 |
| GRFS Grifols S.A. American Depositary Shares | $5.38B | 12.88 | $7.64 | ▲ 1.33% | $8.43$12.15 |
| PBLS Parabilis Medicines Inc. Common Stock | $4.23B | — | $22.75 | ▼ 9.65% | $24.51$42.49 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- UBS Downgrades Acadia Pharmaceuticals to Neutral, Lowers Price Target to $23benzinga · 10/13/2026
- 4 CNS Drug Stocks Worth Watching This World Mental Health DayYahoo · 10/9/2026
- RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Lowers Price Target to $36Benzinga · 10/8/2026
- Acadia Pharmaceuticals (ACAD) Secures Patent And Phase 2 Progress, Is It 38% Below Fair Value?Yahoo · 10/6/2026
- Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041Yahoo · 9/29/2026
- Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041Yahoo · 9/28/2026
- Acadia Pharmaceuticals Announces USPTO Issued Notice Of Allowance For U.S. Patent Application No. 17/590,496, Titled “Methods and Compositions for Treatment of Rett Syndrome.”Benzinga · 9/28/2026
- 3 Stocks Put Traders Are Targeting Today: AMTX, ACAD, REZIYahoo · 9/28/2026
- Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% DropYahoo · 9/27/2026
Insider Activity
Insider Actions →- Schneyer Mark C. · August 6, 2026 · Option Exercise14.3K @ $17.84
- Schneyer Mark C. · August 6, 2026 · Sale9.3K @ $29.34
- Schneyer Mark C. · August 6, 2026 · Sale5.0K @ $29
- Schneyer Mark C. · August 5, 2026 · Option Exercise5.8K @ $17.84
- Schneyer Mark C. · August 5, 2026 · Sale5.8K @ $29
- Thompson Elizabeth H.Z. · July 30, 2026 · Sale50 @ $26.17
- Thompson Elizabeth H.Z. · July 30, 2026 · Sale16.5K @ $26.13
- Thompson Elizabeth H.Z. · July 29, 2026 · Option Exercise32.3K
- BAKER BROS. ADVISORS LP · May 29, 2026 · Grant32.0K
- BAKER BROS. ADVISORS LP · May 29, 2026 · Grant18.6K
- Elizabeth A. Garofalo · May 29, 2026 · Grant9.3K
- Elizabeth A. Garofalo · May 29, 2026 · Grant16.0K
- Elizabeth A. Garofalo · May 29, 2026 · Option Exercise8.1K
- Poole Jonathan · May 29, 2026 · Grant9.3K
- Poole Jonathan · May 29, 2026 · Grant16.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 155.65M
- Total value held
- $3.42B
- Institutional holders
- 336
- Unknown42.90M
- Unknown21.55M
- Unknown8.33M
- Unknown7.14M
- Unknown5.66M
- Unknown3.46M
- Unknown3.34M
- Unknown3.16M
- Unknown2.87M
- Unknown2.61M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates
RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates. RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.